Clinical features and mutation status of EGFR , KRAS , BRAF , EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer

Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 1.4 million deaths every year (1). Despite improvements in early detection and novel treatment for lung cancer in recent years, the prognosis of lung cancer has remained poor, and the 5-year survival is below 20% in most countries, the 5-year survival is about 18% in China (2). There are two major types of lung cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and about 85% of lung cancer is NSCLC, which contains three major histologic subtypes: adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). NSCLC is often diagnosed at an advanced stage (3). For early-stage NSCLC, the standard and potentially efficiency treatment is surgical resection, and for the advanced NSCLC, chemotherapy and target therapy is necessary (4)